Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

1.

[Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].

Ariza R, Van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K.

Farm Hosp. 2014 Jul 1;38(4):257-65. doi: 10.7399/fh.2014.38.4.1137. Spanish.

PMID:
25137158
[PubMed - in process]
Free Article
2.

Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis.

Meadow PB, Nguyen J, Kesavarapu K.

Case Rep Rheumatol. 2014;2014:403452. doi: 10.1155/2014/403452. Epub 2014 Jun 17.

PMID:
25031879
[PubMed]
Free PMC Article
3.

Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study.

Westhovens R, Kremer JM, Emery P, Russell AS, Alten R, Barré E, Dougados M.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):553-62. Epub 2014 Jul 8.

PMID:
25005467
[PubMed - in process]
5.

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis.

Rakieh C, Conaghan PG.

Ther Clin Risk Manag. 2014 Apr 30;10:313-20. doi: 10.2147/TCRM.S60740. eCollection 2014. Review.

PMID:
24812514
[PubMed]
Free PMC Article
6.

Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.

Kremer JM, Peterfy C, Russell AS, Emery P, Abud-Mendoza C, Sibilia J, Becker JC, Westhovens R, Genant HK.

J Rheumatol. 2014 Jun;41(6):1077-87. doi: 10.3899/jrheum.130263. Epub 2014 May 1.

PMID:
24786925
[PubMed - in process]
Free Article
7.

Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.

Picchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S, Laganà B, D'Amelio R, Carsetti R.

Clin Exp Immunol. 2014 Sep;177(3):630-40. doi: 10.1111/cei.12367.

PMID:
24773026
[PubMed - in process]
8.

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.

Takeuchi T, Matsubara T, Urata Y, Suematsu E, Ohta S, Honjo S, Abe T, Yamamoto A, Miyasaka N; Japan Abatacept Study Group.

Mod Rheumatol. 2014 Sep;24(5):744-53. doi: 10.3109/14397595.2014.899179. Epub 2014 Apr 23.

PMID:
24754273
[PubMed - in process]
9.

Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.

Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar CS, Takeuchi T.

Mod Rheumatol. 2014 Apr 7. [Epub ahead of print]

PMID:
24708204
[PubMed - as supplied by publisher]
10.

[Disease modifying antirheumatic drugs].

Luong Ba K, Gabay C.

Rev Med Suisse. 2014 Mar 12;10(421):595-6, 598, 600-2. French.

PMID:
24701712
[PubMed - indexed for MEDLINE]
11.

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.

Wells AF, Jodat N, Schiff M.

Biologics. 2014 Feb 17;8:41-55. doi: 10.2147/BTT.S55783. eCollection 2014. Review.

PMID:
24600202
[PubMed]
Free PMC Article
12.

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R.

J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1.

PMID:
24584926
[PubMed - in process]
Free Article
13.

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

Daïen CI, Morel J.

Mediators Inflamm. 2014;2014:386148. doi: 10.1155/2014/386148. Epub 2014 Jan 12.

PMID:
24523570
[PubMed - in process]
Free PMC Article
14.

Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons.

Barra L, Ha A, Sun L, Fonseca C, Pope J.

Clin Exp Rheumatol. 2014 May-Jun;32(3):333-41. Epub 2014 Jan 24.

PMID:
24480452
[PubMed - indexed for MEDLINE]
15.

[New therapies for rheumatoid arthritis.]

Salgado E, Maneiro JR.

Med Clin (Barc). 2014 Jan 22. pii: S0025-7753(13)00841-5. doi: 10.1016/j.medcli.2013.11.011. [Epub ahead of print] Review. Spanish.

PMID:
24461738
[PubMed - as supplied by publisher]
16.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.

Ann Rheum Dis. 2014 Mar;73(3):529-35. doi: 10.1136/annrheumdis-2013-204575. Epub 2014 Jan 8. Review.

PMID:
24401994
[PubMed - indexed for MEDLINE]
17.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH.

Ann Rheum Dis. 2014 Mar;73(3):516-28. doi: 10.1136/annrheumdis-2013-204577. Epub 2014 Jan 7. Review.

PMID:
24399231
[PubMed - indexed for MEDLINE]
18.

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P.

Arthritis Res Ther. 2014 Jan 2;16(1):R2. doi: 10.1186/ar4427.

PMID:
24383620
[PubMed - in process]
Free PMC Article
19.

Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.

Ikeda K, Sanayama Y, Makita S, Hosokawa J, Yamagata M, Nakagomi D, Takabayashi K, Nakajima H.

Clin Dev Immunol. 2013;2013:697525. doi: 10.1155/2013/697525. Epub 2013 Nov 14.

PMID:
24324510
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

RAISE - rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation.

Dudler J, Tuerk R, Handschin T, Forster A.

Swiss Med Wkly. 2013 Dec 6;143:w13849. doi: 10.4414/smw.2013.13849.

PMID:
24318979
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk